Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich Q4 Revenues Jump 16.7 Percent Atop Increased R&D Spending, Profit

NEW YORK, Feb. 15 (GenomeWeb News) - Sigma-Aldrich yesterday reported a 16.7-percent increase in revenues and a 4.8-percent rise in net income for the fourth quarter.

 

Sales for the three months ended Dec. 31, 2005, rose to $410.5 million from $351.9 million in the year-ago period. The company's scientific research and biotechnology business units increased by 2.7 percent and 12.5 percent, respectively, year over year.

 

R&D expenses for the fourth quarter grew 10 percent to $12.2 million from $11.1 million in Q4 2004, Sigma-Aldrich said.

 

Sigma-Aldrich's net income for the fourth quarter grew to $57.3  million from $54.7 million in Q4 2004.

 

As of Dec. 31, Sigma-Aldrich had approximately $98.6 million in cash and cash equivalents.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.